AUTHOR INDEX

Arthritis Care & Research, Volume 45, Numbers 1–6, 2001

A

Aaron LA, 362
Abbey SE, 519
Abu-Saad HH, 280
Aeschlimann A, 384
Ahern M, 228
Ainiala H, 419
Akama H, 107, 537
Alaranta H, 48
Alarcón GS, 191, 203, 362
Alberts KR, 362
Allaire SH, 174
Allegrante JP, 28, 446
Amor B, 478
Anderson DL, 317
Angst F, 384
Anis AH, 240
Arend WP, 101
Asscher M, 430
Auvinen A, 419
Avdic DM, 392

B

Barlow JH, 77, 159, 378, 424
Barthel HR, 398, 472
Barthelemy B, 129
Bastian HM, 191, 203
Beach S, 410
Beaton DE, 270
Beatty CW, 146
Belza B, 222, 246
Berthelot J-M, 478
Bianchi-Fior P, 129
Bijlsma JWJ, 56, 307
Björvell H, 48
Boey M-L, 494
Bogardus S, 136
Boissier M-C, 129
Bombardier C, 270
Boonen A, 16
Bradley LA, 362
Brauer J, 16
Breban M, 478
Brekke M, 8
Bresnihan B, 485
Briançon S, 111
Brooks K, 203
Brooks PM, 301
Buljina AI, 392
Burant CJ, 340

C

Candel MJJM, 69
Chalmers A, 240
Chamot A-M, 216
Chaplin WF, 362
Cheing GLY, 62
Chisholm R, 533
Chng H-H, 494
Cianfrini LR, 362
Cohen MC, 530
Concato J, 136
Conn DL, 462
Cook RJ, 151
Cormier B, 129
Courtois H, 346
Cross MJ, 301
Crotty M, 228

D

Da Costa D, 355
D'Agostino M-A, 478
Danao LL, 167
Davis AM, 453
de Jonge P, 216
De Witt LP, 69
deHueck A, 519
Dekker J, 56
Dekkers JC, 307
Denis P, 346
Dernis-Labous E, 478
Dewaal DF, 362
Dinant H, 16
Dinant HJ, 324
Doebbeling BN, 398
Dominique S, 346
Domino ML, 362
Dougados M, 478
Driscoll CLW, 146
Duché A, 478
Ducrotté P, 346
Duffy T, 485

E

Edwards J, 1
Elkin EB, 446
Escalante A, 287
Esdaile JM, 240
Evans SR, 174
Evers AWM, 307

F

Fabry DA, 146
Facer GW, 146
Falkenbach A, 430
Farewell VT, 151
Feenstra J, 235
Felson D, 136
Feng P-H, 494
Fessler BJ, 191, 203
Fisher JH, 240
Fitzcharles M-A, 355
Fitzgerald O, 485
Foley RN, 533
Fong K-Y, 494
Fox RI, 473
Fraenkel L, 136
Francke AL, 280
Fransen J, 216
Friedman AW, 191

G

Gabriel SE, 494
Geenen R, 307
Genth E, 430
Gerster J-C, 216
Gladman DD, 151
Godaert GLR, 307
Goei Thè H, 16, 430
Gorter S, 16
Gowans SE, 519
Griep E, 16
Group Français d'Etude Génétique des Spondylarthropathies, 478
Guedes C, 129
Guh D, 240
Guillemin F, 111
Guis S, 478

H

Hainsworth J, 378
Hakala M, 512
Halbert J, 228
Harrington JT, 295
Hazuda HP, 287
Helders PJM, 81
Hellot M-F, 346
Helmick CG, 439
Herings RMC, 235
Herrick AL, 533
Hewett JE, 122
Hidding A, 430
Hietaharju A, 419
Hjortdahl P, 8
Holland GN, 252
Holm MB, 410
Hopman-Rock M, 183
Houben H, 16
Howe H-S, 494
Hui-Chan CWY, 62
Hunder GG, 140, 405, 538
Hunter TB, 392
Hurskainen K, 48
Husted JA, 151
Hutten JBF, 280
Huyse F, 216

I

Ibrahim SA, 340, 372
In 't Veld BA, 235
Inman RD, 475

J

Jabs DA, 252
Jacobi CE, 324
Jentoft ES, 42
Jester R, 1
Johnson DA, 167

K

Kaboli PJ, 398
Kamimaki Y, 35
Kane D, 485
Kasper MJ, 28
Kato S, 35
Katz JN, 270
Katz PP, 263
Keat A, 424
Kersh BC, 362
Koch N, 216
Koh E-T, 494
Koh W-H, 494
Kolopack P, 453
Konttinen YT, 48
Korpela M, 419
Kraaimaat FW, 307
Kvalvik AG, 42
Kvien TK, 8
Kwoh CK, 340, 372

L

Landewé R, 430
Lapsley HM, 301
Lassere M, 485
LaValley MP, 174
Le Blévec G, 478
Leden I, 538
Leeb BF, 537
Leong K-H, 494
Leong K-P, 494
Leufkens HGM, 235
Levesque H, 346
Levinson RD, 252
Lichtenstein MJ, 287
Linssen A, 16
Lisse J, 191
Loeser RF, 331
Lohmander LS, 258
Lorig K, 77
Loukkola J, 419
LUMINA Study Group, 191

M

Macera C, 439
March LM, 301
Marie I, 346
Marra CA, 240
Martin MY, 362
Matteson EL, 108, 146
McConnell S, 453
McDonald TJ, 146
McGwin G Jr., 191
McMurray RW, 86
Mengshoel AM, 42
Mercado U, 108
Merrigan DM, 174
Messier SP, 331
Metsänoja R, 419
Miceli-Richard C, 478
Miller ME, 331
Mitchell P, 246
Moro K, 35
Moum T, 111
Mulherin D, 1
Multon KD, 122
Murphy E, 485

N

Narushima K, 35
Neugebauer A, 263
Niemelä RK, 512
Nilsdotter A-K, 258

O

O'Driscoll BR, 533
O'Fallon WM, 494
Okma-Keulen P, 183

P

Pääkkö E, 512
Padilla GV, 167
Paget SA, 109

AUTHOR INDEX

Arthritis Care & Research, Volume 45, Numbers 1–6, 2001

A

Aaron LA, 362
Abbey SE, 519
Abu-Saad HH, 280
Aeschlimann A, 384
Ahern M, 228
Ainiala H, 419
Akama H, 107, 537
Alaranta H, 48
Alarcón GS, 191, 203, 362
Alberts KR, 362
Allaire SH, 174
Allegrante JP, 28, 446
Amor B, 478
Anderson DL, 317
Angst F, 384
Anis AH, 240
Arend WP, 101
Asscher M, 430
Auvinen A, 419
Avdic DM, 392

B

Barlow JH, 77, 159, 378, 424
Barthel HR, 398, 472
Barthelemy B, 129
Bastian HM, 191, 203
Beach S, 410
Beaton DE, 270
Beatty CW, 146
Belza B, 222, 246
Berthelot J-M, 478
Bianchi-Fior P, 129
Bijlsma JWJ, 56, 307
Björvell H, 48
Boey M-L, 494
Bogardus S, 136
Boissier M-C, 129
Bombardier C, 270
Boonen A, 16
Bradley LA, 362
Brauer J, 16
Breban M, 478
Brekke M, 8
Bresnihan B, 485
Briançon S, 111
Brooks K, 203
Brooks PM, 301
Buljina AI, 392
Burant CJ, 340

C

Candel MJJM, 69
Chalmers A, 240
Chamot A-M, 216
Chaplin WF, 362
Cheing GLY, 62
Chisholm R, 533
Chng H-H, 494
Cianfrini LR, 362
Cohen MC, 530
Concato J, 136
Conn DL, 462
Cook RJ, 151
Cormier B, 129
Courtois H, 346
Cross MJ, 301
Crotty M, 228

D

Da Costa D, 355
D'Agostino M-A, 478
Danao LL, 167
Davis AM, 453
de Jonge P, 216
De Witt LP, 69
deHueck A, 519
Dekker J, 56
Dekkers JC, 307
Denis P, 346
Dernis-Labous E, 478
Dewaal DF, 362
Dinant H, 16
Dinant HJ, 324
Doebbeling BN, 398
Dominique S, 346
Domino ML, 362
Dougados M, 478
Driscoll CLW, 146
Duché A, 478
Ducrotté P, 346
Duffy T, 485

E

Edwards J, 1
Elkin EB, 446
Escalante A, 287
Esdaile JM, 240
Evans SR, 174
Evers AWM, 307

F

Fabry DA, 146
Facer GW, 146
Falkenbach A, 430
Farewell VT, 151
Feenstra J, 235
Felson D, 136
Feng P-H, 494
Fessler BJ, 191, 203
Fisher JH, 240
Fitzcharles M-A, 355
Fitzgerald O, 485
Foley RN, 533
Fong K-Y, 494
Fox RI, 473
Fraenkel L, 136
Francke AL, 280
Fransen J, 216
Friedman AW, 191

G

Gabriel SE, 494
Geenen R, 307
Genth E, 430
Gerster J-C, 216
Gladman DD, 151
Godaert GLR, 307
Goei Thè H, 16, 430
Gorter S, 16
Gowans SE, 519
Griep E, 16
Group Français d'Etude Génétique des Spondylarthropathies, 478
Guedes C, 129
Guh D, 240
Guillemin F, 111
Guis S, 478

H

Hainsworth J, 378
Hakala M, 512
Halbert J, 228
Harrington JT, 295
Hazuda HP, 287
Helders PJM, 81
Hellot M-F, 346
Helmick CG, 439
Herings RMC, 235
Herrick AL, 533
Hewett JE, 122
Hidding A, 430
Hietaharju A, 419
Hjortdahl P, 8
Holland GN, 252
Holm MB, 410
Hopman-Rock M, 183
Houben H, 16
Howe H-S, 494
Hui-Chan CWY, 62
Hunder GG, 140, 405, 538
Hunter TB, 392
Hurskainen K, 48
Husted JA, 151
Hutten JBF, 280
Huyse F, 216

I

Ibrahim SA, 340, 372
In 't Veld BA, 235
Inman RD, 475

J

Jabs DA, 252
Jacobi CE, 324
Jentoft ES, 42
Jester R, 1
Johnson DA, 167

K

Kaboli PJ, 398
Kamimaki Y, 35
Kane D, 485
Kasper MJ, 28
Kato S, 35
Katz JN, 270
Katz PP, 263
Keat A, 424
Kersh BC, 362
Koch N, 216
Koh E-T, 494
Koh W-H, 494
Kolopack P, 453
Konttinen YT, 48
Korpela M, 419
Kraaimaat FW, 307
Kvalvik AG, 42
Kvien TK, 8
Kwoh CK, 340, 372

L

Landewé R, 430
Lapsley HM, 301
Lassere M, 485
LaValley MP, 174
Le Blévec G, 478
Leden I, 538
Leeb BF, 537
Leong K-H, 494
Leong K-P, 494
Leufkens HGM, 235
Levesque H, 346
Levinson RD, 252
Lichtenstein MJ, 287
Linssen A, 16
Lisse J, 191
Loeser RF, 331
Lohmander LS, 258
Lorig K, 77
Loukkola J, 419
LUMINA Study Group, 191

M

Macera C, 439
March LM, 301
Marie I, 346
Marra CA, 240
Martin MY, 362
Matteson EL, 108, 146
McConnell S, 453
McDonald TJ, 146
McGwin G Jr., 191
McMurray RW, 86
Mengshoel AM, 42
Mercado U, 108
Merrigan DM, 174
Messier SP, 331
Metsänoja R, 419
Miceli-Richard C, 478
Miller ME, 331
Mitchell P, 246
Moro K, 35
Moum T, 111
Mulherin D, 1
Multon KD, 122
Murphy E, 485

N

Narushima K, 35
Neugebauer A, 263
Niemelä RK, 512
Nilsdotter A-K, 258

O

O'Driscoll BR, 533
O'Fallon WM, 494
Okma-Keulen P, 183

P

Pääkkö E, 512
Padilla GV, 167
Paget SA, 109

Palardy NR, 362
Parker JC, 122
Patrick DL, 222
Peltola J, 419
Perdriger A, 478
Peterson MGE, 28
Petroski G, 122
Piaseu N, 246
Pöyhiä R, 355
Pratt M, 439

R

Ramsey SD, 222
Rasker JJ, 280
Rat A-C, 129
Reeve RS, 533
Rejeski WJ, 331
Rethans J, 16
Reveille JD, 191
Reynolds WJ, 519
Rhee SH, 122
Robbins L, 109
Robinson MR, 252
Rogers JC, 410
Roorda LD, 56
Roos EW, 258
Roos HP, 258
Roseman J, 191
Rosenbaum JT, 252
Rosenthal GE, 398
Ruchlin HS, 446
Ruggieri AP, 406
Rupp I, 324
Ryan S, 1

S

Saag KG, 398, 468
Said-Nahal R, 478
Saito S, 107, 537
Sakauchi M, 35
Salvarani C, 140
Sanderman R, 111
Santavirta N, 48
Saraux A, 478
Savelkoul M, 69
Scherpbier A, 16
Schulz R, 410
Shaw KL, 159
Silagy C, 228
Silaj A, 519
Siminoff LA, 340
Simon LS, 209
Smarr KL, 122
Smith JR, 252
So AK-L, 216
Solovieva S, 48
Sone H, 35
Sotolongo A, 362
Spencer AC, 222
Stafford L, 485
Starz TW, 410
Steultjens MPM, 56
Stiefel F, 216
Stricker BHC, 235
Strome SE, 146
Stucki G, 384
Stucky RC, 122
Sturkenboom MCJM, 235
Suramo I, 512
Suurmeijer TPBM, 111
Suzuki N, 35

T

Takalo R, 512
Takita T, 35
Takken T, 81
Taljanovic MS, 392
Tarasuk V, 270
Temmink D, 280
Thio S-T, 494
Thumboo J, 494
Topolski TD, 222
Triana-Alexander M, 362
Tribe KL, 301
Triemstra M, 324

U

Uramoto K, 494

V

Van den Borne B, 69
Van den Bos GAM, 324
Van den Heuvel WJA, 111
Van der Heijde D, 16, 430
Van der Horst-Bruinsma I, 16
Van der Linden PD, 235
Van der Linden S, 16, 430
Van der Net J, 81
Van der Tempel H, 16, 69
Van der Vleuten C, 16
Van der Zee J, 280
Van Puijenbroek EP, 235
Van Santen-Hoeufft M, 16
Van Sonderen FLP, 111
Van Tubergen A, 430
Voss S, 519

W

Walker SE, 122
Walsh MB, 295
Waltz M, 111
Wang G, 439
Weller D, 228
Westby MD, 501
Westerlund JP, 258
Westgeest T, 16
Whitcup SM, 252
Williams B, 424
Wolter N, 430
Wright CC, 77, 159, 424
Wright GE, 122
Wright JG, 270
Wutzl AL, 533

Y

Yamazaki Y, 35
Youssef PP, 485

Z

Zhang P, 439

SUBJECT INDEX

Arthritis Care & Research, Volume 45, Numbers 1–6, 2001

A

Achilles tendon rupture, fluoroquinolones and, 235
Activities of daily living, in OA, task independence, safety, and adequacy in older women, 410
Adjunctive medical therapy, for SLE, 86
Aerobic exercise
  fibromyalgia, aquatic and land-based aerobic exercise for women, 42
  guide for arthritis patients, 501
African American population
  OA, perceptions on complementary treatment/self-care, 340
  sociocultural issues in clinical research, 203
Alternative medicine. *See* Complementary and alternative medicine
Americans With Disabilities Act (ADA), use by patients with rheumatic diseases, 174
Androgens, for SLE, 91
Ankylosing spondylitis (AS)
  combined spa-exercise therapy for, 430
  etanercept for refractory disease, 404
  rheumatologists' performance assessment by "standardized patients" method, 16
  work disability and, 424
Anti-thymocyte globulin, for SLE, 86
Aquatic exercise
  for fibromyalgia, 42
  for JIA, 81
Arthritis Care and Research, new series of articles, 405
Australia, OA, patient expenditures, health status, and social impact, 301
Autoimmune hearing loss, MTX as treatment for, 146

B

B cell tolerization, for SLE, 91
Bromocriptine, for SLE, 93

C

Cardiopathy, and RA, 129
Case complexity, and health care utilization by RA patients, 216
Caucasian population
  OA, perceptions on complementary treatment/self-care, 340
  SLE clinical manifestations, comparative study with Chinese population, 494
  sociocultural issues in clinical research, 205
Center for Epidemiological Studies-Depression (CES-D) Scale, cross-cultural comparison, UK and US, 77
Children's Arthritis Self-Efficacy Scale, development and preliminary validation of, 159
Chinese population
  motor dysfunction of knee OA patients, 62
  SLE clinical manifestations, comparative study with Caucasian population, 494
Chloroquine, for SLE, 86
Chondroitin, for OA, 107, 537
Ciprofloxacin, tendon disorders attributed to, 235
Civil rights legislation, use of ADA by patients with rheumatic diseases, 174
Cladribine, for SLE, 86
Cogan's syndrome, autoimmune hearing loss, MTX as treatment for, 146
Communication, preference for disclosure of information among patients, 136
Complementary and alternative medicine
  for OA, older adults, 222
  for OA, perceptions of African American and white older adults, 340
  use by older arthritis patients, 398
Coping intervention, effect on patients with rheumatic diseases, 69
Coping strategies
  in hemophilia, 48
  in RA, biopsychosocial interactions in, 307
Cortisone, RA, low-dose glucocorticoids for, pro and con, 462, 468
COX-2 inhibition, overview, 209
Cross-cultural research
  overview, 109
  Quality of Life-Rheumatoid Arthritis Scale in English and Spanish, 167
  sociocultural issues in clinical research, 203
  test instrument comparisons, UK and US, 77
Cyclosporine, for SLE, 86
Cylosporin A, for RA, effectiveness and toxicity of, 240
Cytokines, in RA, 101

D

Depression, in RA patients, satisfaction with abilities and, 263
Disability
  AS, work disability in patients, 424
  change in physical functioning in older adults with knee pain, OASIS study, 331
  in hemophilia, 48
  in OA, responsiveness of disability measures in, 56
  in OA, task independence, safety, and adequacy in older women, 410
Disease-modifying antirheumatic drugs (DMARDs), for RA, 240, 530

E

Echocardiography, cardiac manifestations of RA, 129
Economic impact
  inactivity-associated medical costs in adults with arthritis, 439
  patient education and high-intensity strength intervention following hip fracture, 446
Elderly adults. *See* Older adults
Eponymic idiopathic vasculitis, 108
Erythrocyte sedimentation rate (ESR)
  GCA with low ESR, 140
  quality of life in early RA, EURIDISS study, 111
Esophageal involvement, of SSc, 346
Etanercept
  for inflammatory eye disease associated with rheumatic disease, 252
  for refractory AS, 404
Ethnic differences, OA, perceptions of African American and white older adults, 340
Ethnic differences. *See also* Cross-cultural research
Ethnic groups, in SLE, predictors of early mortality, 191, 306
European Research on Incapacitating Disease and Social Support (EURIDISS), quality of life profiles in early RA, 111
Exercise
  aerobic fitness activities, 501
  AS, combined spa-exercise therapy for, 430
  fibromyalgia, aquatic and land-based aerobic exercise for women, 42
  fibromyalgia, exercise, mood and physical function in, 519
  hip fracture, strength intervention following, economic impact, 446
  OA, primary care-based physical activity programs, effectiveness in sedentary older patients, 228
  rheumatoid hand, physical and exercise therapy for, 392
Exercise for Older Adults Project, 228
Eyes, TNF inhibition in inflammatory eye disease, 252

F

Family studies, spondylarthropathy, phenotypic diversity, 478
Fatigue, quality of life in early RA, EURIDISS study, 111
Fibromyalgia
  aquatic and land-based aerobic exercise for women, 42
  exercise and mood and physical function in, 519
  health care seeking in, 362
  pain and pain relief in, 355
  psychosocial and health status variables as predictors of health care-seeking, 362
  rheumatologists' performance assessment by "standardized patients" method, 16
Fluoroquinolones, tendon disorders attributed to, 235
Fracture
  hip, patient education and high-intensity strength intervention, 446
  vertebral, rheumatologists' performance assessment by "standardized patients" method, 16
Function
  change in physical functioning in older adults with knee pain, OASIS study, 331
  fibromyalgia, exercise and mood and physical function in, 519
  rheumatoid hand, physical and exercise therapy for, 392
  total hip replacement, responsiveness of measures of, 258
Functional Assessment System, total hip replacement, responsiveness of measures of pain and function after, 258

G

Gait analysis, kinematic approach to, in knee RA, 35
Gastroesophageal reflux, in SSc, 346
Giant cell arteritis (GCA), with low ESR, 140
Glucocorticoids, for RA, pros and cons, 462, 468
Glucosamine, for OA, 107, 537

H

Hand, physical and exercise therapy for rheumatoid hand, 392
Health care delivery
  pre-appointment management of new patient referrals, 295
  RA, health care involvement and satisfaction, 8
  RA, inpatient care experience, 1
  rheumatologists' performance assessment by "standardized patients" method, 16
Health care seeking, in fibromyalgia, psychosocial and health status variables as predictors of, 362
Health care utilization
  in RA, case complexity and, 216
  in RA, sociodemographic variables and, 324
Health-related quality of life
  of PsA patients, compared with RA patients, 151
  Quality of Life-Rheumatoid Arthritis Scale in English and Spanish, 167
Health status
  fibromyalgia, health care-seeking behavior and, 362
  health and symptom status outcomes, patient and physician concordance on, 372
  OA, patient expenditures, health status, and social impact, 301
Healthcare costs
  inactivity-associated medical costs in adults with arthritis, 439
  "out-of-pocket" expenditures for OA, 301
  patient education and high-intensity strength intervention following hip fracture, 446
Hearing loss, MTX as treatment for autoimmune hearing loss, 146
Heart. *See* Cardiopathy
Hemachromatosis arthropathy, rheumatologists' performance assessment by "standardized patients" method, 16
Hemophilia, coping strategies, pain, and disability in, 48
Hip
  disability in OA, responsiveness of disability measures in, 56
  hip fracture, patient education and high-intensity strength intervention, 446
  range of motion, walking velocity in aged persons and, 287
Hip replacement, pain and function after, 258
Hispanic population
  sociocultural issues in clinical research, 205
  walking velocity in aged persons, 287
Hormonal therapies, for SLE, 91
Hospitalization, RA, patient experience with, 1
Hydrotherapy, AS, combined spa-exercise therapy for, 430

I

Imaging, noninvasive studies of parotid glands in SS, 473, 512
Immunoadsorption, for SLE, 91
Immunosuppressants, for SLE, 86
Inactivity, medical costs associated with inactivity in adults with arthritis, 439
Inflammatory eye disease, TNF inhibition in, 252
Infliximab, TNF inhibition in inflammatory eye disease associated with rheumatic disease, 252
Inpatient care, RA, patient experience with, 1
INTERMED, case complexity and health care utilization by RA patients, 216
Interstitial lung disease, in SSc, 346
Intravenous immunoglobulin, for SLE, 86

J

Juvenile idiopathic arthritis (JIA)
  aquatic exercise and, 81
  Children's Arthritis Self-Efficacy Scale, 159

K

Kidneys. *See* Renal
Knee
  change in physical functioning in older adults with knee pain, OASIS study, 331
  disability in OA, responsiveness of disability measures in, 56
  motor dysfunction of knee OA patients, 62
  RA, kinematic approach to gait analysis, 35
  range of motion, walking velocity in aged persons and, 287

L

Land-based exercise, for women with fibromyalgia, 42
Lateral epicondylitis, rheumatologists' performance assessment by "standardized patients" method, 16
Lay leaders, volunteers' experiences of becoming, 378
Leflunomide
  for RA, 530
  for SLE, 472
5-Lipoxygenase inhibitor, for SLE, 86
Lungs. *See* Pulmonary dysfunction

M

Magnetic resonance imaging (MRI), of parotid glands in SS, 473, 512
Magnetic resonance sialography, of parotid glands in SS, 473, 512
Medical costs
  inactivity-associated, in adults with arthritis, 439
  patient education and high-intensity strength intervention following hip fracture, 446
Medical Outcomes Study 36-item Short Form (SF-36)
  OA, patient expenditures, health status, and social impact, 301
  OA, sample sizes, 384
  total hip replacement, responsiveness of measures of pain and function after, 258
Meniere's disease, MTX for autoimmune hearing loss, 146
Methotrexate (MTX)
  for autoimmune hearing loss, 146
  for RA, combination cyclosporin A/MTX therapy, 240
  for SLE, 86
Mexican American population, walking velocity in aged persons, 287
Microscopic polyangiitis, case history, pulmonary-renal syndrome in SSc patient, 533

Minimal clinically important difference (MCID), in rehabilitation intervention studies, 384
Mobility, disability in OA, responsiveness of disability measures in, 56
Monoclonal antibodies, for SLE, 91
Mood, fibromyalgia, exercise and mood and physical function in, 519
Mortality, SLE, predictors of early mortality in LUMINA cohort, 191, 306
Musculoskeletal pain, health care involvement and satisfaction, 8
Mycophenolate mofetil, for SLE, 86

N

Netherlands
  AS, combined spa-exercise therapy for, 430
  outpatient nurse clinics, 280
  rheumatologists' performance assessment by "standardized patients" method, 16
Neuropsychiatric lupus
  ACR criteria for, 419
  nomenclature, classification, and criteria, 406
Nonstandard medical therapy, for SLE, 86
Norfloxacin, tendon disorders attributed to, 235
Norwegian population, RA, health care involvement and satisfaction, 8
Nurse clinics, use in Netherlands, 280

O

Observational Arthritis Study in Seniors (OASIS), change in physical functioning in older adults with knee pain, 331
Ofloxacin, tendon disorders attributed to, 235
Older adults
  change in physical functioning in older adults with knee pain, OASIS study, 331
  complementary and alternative medicine, use by arthritis patients, 398
  OA, alternative therapies, 222
  OA, factors associated with onset in older women, 183
  OA, perceptions on complementary treatment/self-care, 340
  OA, primary care-based physical activity programs, effectiveness in sedentary patients, 228
  OA, task independence, safety, and adequacy in older women, 410
  volunteer lay leaders' experiences as leaders, 378
  walking velocity in aged persons, range of motion and, 287
Osteoarthritis (OA)
  alternative therapies used by older adults, 222
  change in physical functioning in older adults with knee pain, OASIS study, 331
  COX-2 inhibition, overview, 209
  exercise advice for older OA patients, 228
  factors associated with onset in older women, 183
  glucosamine and chondroitin for, 107, 537
  motor dysfunction of knee OA patients, 62
  patient expenditures, health status, and social impact, 301
  perceptions on complementary treatment/self-care, 340
  quality of life measurement, sample size and, 384
  responsiveness of disability measures in, 56
  task independence, safety, and adequacy in older women, 410
  total hip replacement, responsiveness of measures of pain and function after, 258
  WOMAC, utility and measurement properties, 453
Osteoporosis, rheumatologists' performance assessment by "standardized patients" method, 16
Osteoporosis prevention
  education program for young women, testing, 246
  need for comprehensive programs for young women, 28
"Out-of-pocket" expenditures, for OA, 301
Outcome
  health and symptom status outcomes, patient and physician concordance on, 372
  meaning of recovery, "are you better?," 270
Outcome *(cont'd)*
  SLE, predictors of early mortality in LUMINA cohort, 191, 306
  spondylarthropathy, psoriasis as predictor of short-term outcome, 485
Outpatient nurse clinics, use in Netherlands, 280

P

Pain
  after total hip replacement, 258
  in fibromyalgia, 355
  in hemophilia, 48
  measurement, Rheumatoid Arthritis Pain Scale, 317
  musculoskeletal, health care involvement and satisfaction, 8
  quality of life in early RA, EURIDISS study, 111
  RA, stress management effects on, 122
Parotid glands, MRI and magnetic resonance sialography of parotid glands in SS, 473, 512
Patient education
  coping intervention, effect on patients with rheumatic diseases, 69
  following hip fracture, economic impact, 446
  outpatient nurse clinics, 280
  primary care-based physical activity programs, effectiveness in sedentary OA older patients, 228
  stress management, effect on pain behavior in RA, 122
  volunteers' experiences as arthritis self-management lay leaders, 378
Patient perceptions
  meaning of recovery, "are you better?," 270
  OA, perceptions of treatment and self-care practices in African American and white older adults, 340
  RA, depression, activities, and satisfaction, 263
  RA, health care involvement and satisfaction, 8
  RA, inpatient care experience, 1
Patient preferences
  on disclosure of treatment and risk information, 136
  health and symptom status outcomes, patient and physician concordance on, 372
Pefloxacin, tendon disorders attributed to, 235
Phenotypic diversity, spondylarthropathy, 478
Physical activity, inactivity-associated medical costs in adults with arthritis, 439
Physical functioning
  change in older adults with knee pain, OASIS study, 331
  fibromyalgia, exercise and mood and physical function in, 519
Physical therapy
  AS, combined spa-exercise therapy for, 430
  rheumatoid hand, physical and exercise therapy for, 392
Physicians
  patient and physician concordance on health and symptom status outcomes, 372
  pre-appointment management of new patient referrals, 295
  rheumatologists' performance assessment by "standardized patients" method, 16
Plasmapheresis, for SLE, 91
Polymyalgia rheumatica, rheumatologists' performance assessment by "standardized patients" method, 16
Population-based study
  ACR criteria for neuropsychiatric lupus, validity of, 419
  complementary and alternative medicine, use by older arthritis patients, 398
  GCA with low ESR, 140
Practice management, pre-appointment management of new patient referrals, 295
Predictors
  fibromyalgia, health care seeking in, 362
  of health care-seeking in fibromyalgia, 362
  OA, onset of in older women, 183
  SLE, predictors of early mortality in LUMINA cohort, 191, 306
  spondylarthropathy, psoriasis as predictor of short-term outcome, 485
Prednisone, RA, low-dose glucocorticoids for, pro and con, 462, 468

Primary prevention programs
osteoporosis education, testing effectiveness of in young women, 246
osteoporosis prevention, need for comprehensive programs for young women, 28
Psoriasis, as predictor of short-term outcome in spondylarthropy, 485
Psoriatic arthritis (PsA)
health-related quality of life compared with RA patients, 151
rheumatologists' performance assessment by "standardized patients" method, 16
Psychometrics. *See* Test instruments
Psychosocial variables
in fibromyalgia, health care-seeking behavior and, 362
in RA, 307
Pulmonary dysfunction
microscopic polyangiitis case history, pulmonary-renal syndrome in SSc patient, 533
SSc, interstitial lung disease in, 346

Q

Quality of life
in early RA, EURIDISS study, 111
in OA, measurement instruments, sample size, 384
of PsA patients, compared with RA patients, 151
Quality of Life-Rheumatoid Arthritis Scale in English and Spanish, 167

R

Range of motion, walking velocity in aged persons and, 287
Reactive arthritis, psoriasis as predictor of short-term outcome, 485
Recovery, meaning of recovery, "are you better?," 270
Rehabilitation intervention, effects and sample sizes and, 384
Reiter's syndrome, psoriasis as predictor of short-term outcome, 485
Renal dysfunction, microscopic polyangiitis case history, pulmonary-renal syndrome in SSc patient, 533
Repetitive strain injuries, meaning of recovery, "are you better?," 270
Rheumatic diseases
coping intervention in, effects, 69
TNF inhibition in inflammatory eye disease associated with, 252
use of ADA by patients, 174
Rheumatoid arthritis (RA)
biopsychosocial interactions in, 307
cardiac manifestations of, 129
case complexity and health care utilization by RA patients, 216
combination cyclosporin A/MTX therapy, 240
COX-2 inhibition, overview, 209
cytokine pathways in, 101
depression, activities, and satisfaction, 263
in Egyptian mummies, 538
gait analysis, kinematic approach to in knee RA, 35
health care involvement and satisfaction, 8
health care utilization, 324
health-related quality of life compared with PsA patients, 151
low-dose glucocorticoids for, pro and con, 462, 468
patient experience with inpatient care, 1
physical and exercise therapy for rheumatoid hand, 392
preference for disclosure of information among patients, 136
quality of life profiles, EURIDISS study, 111
Quality of Life-Rheumatoid Arthritis Scale in English and Spanish, 167
Rheumatoid Arthritis Pain Scale, 317
rheumatologists' performance assessment by "standardized patients" method, 16
stress management, effect on pain behavior in, 122
treatment options for, 530
Rheumatoid Arthritis Pain Scale, development of, 317
Rheumatologists. *See* Physicians
Ritchie Articular Index, quality of life in early RA, EURIDISS study, 111

S

Sample size, in rehabilitation intervention studies, 384
San Antonio Longitudinal Study of Aging, walking velocity in aged persons, 287
Scleritis, TNF inhibition in inflammatory eye disease associated with rheumatic disease, 252
Self-care
OA, perceptions of, ethnic differences, 340
volunteer lay leaders' experiences as leaders, 378
Sialography, magnetic resonance sialography of parotid glands in SS, 473, 512
Sjögren's syndrome (SS), MRI and magnetic resonance sialography of parotid glands in, 473, 512
Smallest detectable difference, in rehabilitation intervention studies, 384
Social impact, OA, patient expenditures, health status, and social impact, 301
Sociocultural issues, in clinical research, 203
Spa therapy, AS, combined spa-exercise therapy for, 430
Spondylarthropathies
clinical stratification in, 475
phenotypic diversity, 478
psoriasis predicts poor short-term outcome in, 485
Stem cell transplantation, for SLE, 91
Strength intervention, following hip fracture, economic impact, 446
Stress, RA, biopsychosocial interactions in, 307
Stress management, effect on pain behavior in RA, 122
Susceptibility, factors associated with onset of OA in older women, 183
Symptom status, health and symptom status outcomes patient and physician concordance on, 372
Synovitis, cytokine pathways in RA, 101
Systemic lupus erythematosus (SLE)
clinical manifestations, comparative study of Caucasians and Chinese populations, 494
leflunomide for treatment, 472
neuropsychiatric lupus, ACR criteria for, 419
neuropsychiatric lupus, nomenclature, classification, and criteria, 406
nonstandard and adjunctive medical therapies for, 86
predictors of early mortality in LUMINA cohort, 191, 306
Systemic sclerosis (SSc)
esophageal involvement and pulmonary manifestations in, 346
microscopic polyangiitis presenting as pulmonary-renal syndrome in SSc patient, 533

T

Tacrolimus, for SLE, 86
Tender joint count, quality of life in early RA, EURIDISS study, 111
Tendon disorders, fluoroquinolones and, 235
Test instruments
Children's Arthritis Self-Efficacy Scale, 159
cross-cultural comparisons, UK and US, 77
Quality of Life-Rheumatoid Arthritis Scale in English and Spanish, 167
responsiveness of measures of pain and function after total hip replacement, 258
Rheumatoid Arthritis Pain Scale, 317
Thailand, osteoporosis educational program, testing effectiveness on in young women, 246
Total hip replacement, pain and function after, 258
Transmural rheumatology nurse clinics, use in Netherlands, 280
Transthoracic echocardiography, cardiac manifestations of RA, 129

Treatment-related risks, preference for disclosure of information among RA patients, 136
Tumor necrosis factor (TNF) inhibition, in inflammatory eye disease, 252

U

Undifferentiated spondylarthropathy, psoriasis as predictor of short-term outcome, 485
United Kingdom
  CES-D Scale, cross-cultural comparisons, UK and US, 77
  volunteer lay leaders' experiences as leaders, 378
United States, CES-D Scale, cross-cultural comparisons, UK and US, 77
Uveitis, TNF inhibition in inflammatory eye disease associated with rheumatic disease, 252

V

Vasculitis
  eponymic idiopathic vasculitis, 108
  microscopic polyangiitis presenting as pulmonary-renal syndrome in SSc patient, 533
Vertebral fracture, rheumatologists' performance assessment by "standardized patients" method, 16
Vincristine, for SLE, 86
Volunteers, self-management lay leaders' experiences as leaders, 378
Von Willebrand's disease, coping strategies, pain, and disability in, 48

W

Wegener's granulomatosis (WG), eponymic idiopathic vasculitis history, 108
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
  OA, patient expenditures, health status, and social impact, 301
  sample sizes, in OA patients, 384
  total hip replacement, responsiveness of measures of pain and function after, 258
  utility and measurement properties, 453
Widespread muscle pain, aquatic and land-based aerobic exercise for women, 42
Work disability, in AS patients, 424

Y

Young women
  osteoporosis educational program, testing effectiveness on, 246
  osteoporosis prevention program, need for in, 28

Z

Zileutin, for SLE, 86